SU

Surmodics IncFRA Surmodics Stock Report

Last reporting period 30 Sep, 2024

Updated —

Last price

Market cap $B

0.558

Micro

Exchange

XFRA - Deutsche Boerse AG

SU6.F Stock Analysis

SU

Uncovered

Surmodics Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

2/100

Low score

Market cap $B

0.558

Dividend yield

Shares outstanding

14.125 B

Surmodics, Inc. engages in the provision of surface modification technologies for intravascular medical devices and chemical components for in vitro diagnostic immunoassay tests and microarrays. The company is headquartered in Eden Prairie, Minnesota and currently employs 447 full-time employees. The firm operates through two segments: Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment manufactures performance coatings, including surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices, as well as drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device, with end markets that includes coronary, peripheral, neurovascular and structural heart, among others. The IVD segment designs, develops and manufactures component products and technologies for diagnostic immunoassay, as well as molecular tests and biomedical research applications, with products that include protein stabilizers, substrates, surface coatings and antigens.

View Section: Eyestock Rating